Aptevo Therapeutics Inc.
Business
Aptevo Therapeutics is a clinical-stage biotechnology company developing novel immunotherapy candidates for cancer treatment using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. The company has two clinical candidates—mipletamig for acute myeloid leukemia and ALG.APV-527 for solid tumors—and six preclinical candidates. Aptevo operates through internal research and development and a collaboration with Alligator Bioscience for ALG.APV-527 development. The company pursues regulatory approval and commercialization partnerships to advance its pipeline globally.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | −15 | −14 | −17 | −18 | −19 | |
| General and administrative | −12 | −10 | −12 | −14 | −15 | |
| Loss from operations | −26 | −25 | −29 | −29 | −21 | |
| Other income, net | 345,000 | 472,000 | 578,000 | −4 | −8 | |
| Net loss | −26 | −24 | −19 | 7 | −29 | |
| Dividend attributable to down round feature of warrants | −2 | — | — | — | — | |
| Net loss attributable to common stockholders | −28 | −24 | — | — | — | |
| Basic net loss per share | −87.27 | −31,460 | −2,317 | 1.57 | −6.07 | |
| Diluted net loss per share | −87.27 | −31,460 | −2,317 | 1.57 | −6.07 | |
| Basic shares used in calculation | 315,535 | 767 | 7,515 | 5 | 5 | |
| Diluted shares used in calculation | 315,535 | 767 | 7,515 | 5 | 5 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-05-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 22 | 9 | 17 | 23 | — | |
| Prepaid expenses and other current assets | 1 | 2 | — | — | — | |
| Total current assets | 23 | 11 | 19 | 27 | — | |
| Property and equipment, net | 303,000 | 543,000 | 895,000 | 1 | — | |
| Operating lease right-of-use asset | 4 | 4 | 5 | 5 | 4 | |
| Total assets | 27 | 16 | 25 | 34 | — | |
| Accounts payable | 877,000 | 1 | — | — | — | |
| Accrued expenses and other current liabilities | 4 | 4 | — | — | — | |
| Operating lease liability, current portion | 900,000 | 800,000 | — | — | — | |
| Total current liabilities | 6 | 6 | 7 | 9 | — | |
| Operating lease liability, net of current portion | 4 | 5 | 5 | 6 | — | |
| Total liabilities | 10 | 11 | 13 | 16 | — | |
| Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding | — | — | — | — | — | |
| Common stock: $0.001 par value; 500,000,000 shares authorized; 997,830 and 4,051 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 114,000 | 84,000 | 61,000 | 48,000 | — | |
| Additional paid-in capital | 292 | 252 | 236 | 224 | — | |
| Accumulated deficit | −275 | −248 | −223 | −206 | — | |
| Total stockholders' equity | 17 | 5 | 12 | 18 | — | |
| Total liabilities and stockholders' equity | 27 | 16 | 25 | 34 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −26 | −24 | −17 | 8 | −28 | |
| Stock-based compensation | 96,000 | 1 | 2 | 2 | 2 | |
| Non-cash lease expense | 1 | 1 | — | — | — | |
| Depreciation and amortization | 240,000 | 352,000 | 567,000 | 901,000 | 1 | |
| Prepaid expenses and other current assets | 483,000 | 217,000 | 153,000 | 355,000 | 436,000 | |
| Accounts payable, accrued compensation, accrued expenses and other current liabilities, and short-term operating lease | −157,000 | −1 | 518,000 | −394,000 | −2 | |
| Operating lease liability | −1 | −1 | — | — | — | |
| Net cash used in operating activities | −26 | −24 | −12 | −21 | −22 | |
| Net cash from investing activities | 0 | 0 | 0 | −29,000 | −713,000 | |
| Value of equity awards withheld for tax liability | 0 | −1,000 | −10,000 | −4,000 | — | |
| Proceeds from exercise of common warrants, net of issuance costs | 557,000 | 6 | 3 | — | 1 | |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | 38 | 10 | 6 | 7 | 10 | |
| Payments in lieu of fractional shares | — | −3,000 | — | — | — | |
| Net cash provided by financing activities | 38 | 16 | 6 | −3 | 26 | |
| Increase (decrease) in cash and cash equivalents | 13 | −8 | −6 | −24 | 4 | |
| Warrant modification - incremental value | 586,000 | 472,000 | 2 | — | — | |
| Fair value of December 2024 inducement transaction common warrants | — | 7 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Aptevo Therapeutics Inc.'s CIK number?
Aptevo Therapeutics Inc.'s SEC CIK number is 0001671584 (1671584). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Aptevo Therapeutics Inc.'s SEC filings?
All of Aptevo Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Aptevo Therapeutics Inc. last report earnings?
Aptevo Therapeutics Inc. (APVO) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-221593). This is Aptevo Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Aptevo Therapeutics Inc.'s most recent earnings 8-K?
Aptevo Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001193125-26-221593. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Aptevo Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →